The role of dronedarone in the modern antiarrhythmic therapy Review article
Article Sidebar
Main Article Content
Abstract
Atrial fibrillation (AF) is one of the most common arrhythmia. Treatment of AF consists of rhythm control or rate control and prevention of thromboembolic events. For many years, conducted a study on the introduction of new, effective and safe anti-arrhythmic drugs, and therefore have high hopes associated with dronedarone. On the basis of DAFNE, EURIDIS, ADONIS and DIONYSOS demonstrated that dronedarone is effective in maintaining normal sinus rhythm than placebo and less effective than amiodarone. At the same time it was noted that the chronic use of dronedarone is associated with fewer side effects, and the same it is more acceptable drug than amiodarone. ANDROMEDA and PALLAS trial were terminated prematurely, its demonstrate restriction using of dronedarone. That why in 2012 guidelines of ESC was updated. Currently dronedarone is contraindicated in heart failure, and even in asymptomatic left ventricular systolic dysfunction. In ischemic heart disease, dronedarone has become a second- line drug, giving priority sotalol. Maintains the possibility of using dronedarone in non-severe structural heart disease and hypertension complicated by cardiac hypertrophy. Research on dronedarone showed that the drug is a poor competitor for other, older anti-arrhythmic drugs.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Dale K.M., White C.M.: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann. Pharmacother. 2007; 41(4): 599-605.
3. Tafreshi M.J., Rowles J.: A review of the investigational antiarrhythmic agent dronedarone. J. Cardiovasc. Phamacol. Ther. 2007; 12(1): 15-26.
4. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 2002; 47: 1825-33.
5. Hagens V.E., Crijns H.J., Van Veldhuisen D.J. et al.; RAte Control versus Electrical cardioversion for persistent atrial fibrillation study group: Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am. Heart J. 2005; 149(6): 1106-11.
6. Opolski G., Torbicki A., Kosior D.A. et al.; Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study: Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126(2): 476-86.
7. Cleland J.G., Coletta A.P., Abdellah A.T. et al.: Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy. Eur. J. Heart Fail. 2008; 10(1): 102-8.
8. Camm A.J., Kirchhof P., Lip G.Y. et al.; ESC Committee for Practice Guidelines, Vahanian A, Auricchio A, Bax J et al.: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420.
9. Kathöfer S., Thomas D., Karle C.A.: The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc. Drug Rev. 2005; 23(3): 217-230.
10. Patel P.D., Bhuriya R., Patel D.D. et al.: Dronedarone for atrial fibrillation: a new therapeutic agent. Vasc. Health Risk. Manag. 2009; 5: 635-642.
11. Manning A., Thisse V., Hodeige D. et al.: SR 33589, a new amiodarone-like antiarrhytmic agent: electrophysiological effects in anesthetized dogs. J. Cardiovasc. Pharmacol. 1995; 25: 252-261.
12. Gautier P., Guillemare E., Marion A. et al.: Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J. Cardiovasc. Pharmacol. 2003; 41(2): 191-202.
13. Hodeige D., Heyndrickx J.P., Chatelain P. et al.: SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur. J. Pharmacol. 1995; 279(6): 25-32.
14. Guiraudou P., Pucheu S.C., Gayraud R. et al.: Involvement of nitric oxide in amiodarone- and dronedarone-induced coronary vasodilation in guinea pig heart. Eur. J. Pharmacol. 2004; 496(8): 119-127.
15. Manning A., Hodeige D., Richard J. et al.: SR 33589, A new amiodarone-like antiarrhytmic agent: electrophysiological effects in dogs. Br. J. Pharmacol. 1994; 112 (Proc. Suppl.): 579P.
16. Manning A.S., Bruyninckx C., Hodeige D. et al.: SR 33589 A new amiodarone-like antiarrhytmic agent. Br. J. Pharmacol. 1992; 107 (Proc. Suppl.): 270P.
17. Le Grand B.: Dronedarone. Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs 2000; 2: 36-39.
18. Oyetayo O.O., Rogers C.E., Hofmann P.O.: Dronedarone: a new antiarrhythmic agent. Pharmacotherapy 2010; 30(9): 904-915.
19. Touboul P., Brugada J., Capucci A. et al.: Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur. Heart J. 2003; 24(8): 1481-1487.
20. Sun W., Sarma J.S.M., Singh B.N.: Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart. Comparison with amiodarone. Circulation 1999; 100: 2276-2281.
21. Brenner R., Delacretaz E.: Dronedaron for the management of atrial fibrillation. Swiss Medical Weekly 2011 [online: DOI: 10.4414/smw.2011.13158].
22. Schweizer P., Becker R., Katus H. et al.: Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des. Devel. Ther. 2011; 5: 27-39.
23. Patel C., Yan G., Kowey P.: Dronedarone. Circulation 2009; 120: 636-644.
24. Camm A.J., Lip G.Y.H., Caterina R. et al.: Wytyczne ESC dotyczące postępowania w migotaniu przedsionków na 2012 rok. Uaktualnienie wytycznych Europejskiego Towarzystwa Kardiologicznego (ESC) dotyczących postępowania w migotaniu przedsionków z 2010 roku opracowane przy współpracy z European Heart Rhythm Association (EHRA). Kardiologia Polska 2012; 70(supl. IV): 197-234.
25. European Medicines Agency Press Release, 22 September 2011; EMA/CHMP/718819/2011 Press Office [online: www.ema.europa.eu].
26. Pollak P.T., Shafer S.L.: Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin. Pharmacol. Ther. 2004; 75(4): 342-351.
27. Tschuppert Y., Buclin T., Rothuizen L.E. et al.: Effect of dronedarone on renal function in healthy subjects. Br. J. Clin. Pharmacol. 2007; 64(6): 785-791.
28. Sanofi Avensis Sp. z.o.o. Informacje dotyczące przypadków ciężkiego uszkodzenia wątroby związanych ze stosowaniem leku Multaq (dronedaron); Warszawa, 21 stycznia 2011 r.
29. Charakterystyka produktu leczniczego. Proponowana wersja polska w trakcie weryfikacji tłumaczenia przez Urząd Rejestracji PLWMiPB w ramach procedury centralnej. 26 listopada 2009. Sanofi Avensis Sp. z.o.o.
30. Salam A.M.: Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial. Expert Rev. Cardiovasc. Ther. 2012; 10(11): 1345-9.
31. Sanofi Aventis Sp. z.o.o. Komunikat dotyczący ograniczenia stosowania produktu leczniczego Multaq (dronedaron). 30 września 2011 r.